FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
31 letters match. Newest first.
-
DrugsZhejiang Gaorong Cosmetic Co., Ltd.
FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.
High risk -
DrugsTCI Co., Ltd BioCosme PABP BRANCH
FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.
High risk -
DrugsPine Pharmaceuticals, LLC
FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.
High risk -
DrugsBabikian Healthcare Products CJSC
FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.
High risk -
DrugsCuria New York, Inc.
FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.
High risk -
FoodAmerican Pharma Mfg. Inc.
FDA warns American Pharma Mfg. of serious dietary supplement manufacturing violations at its Ontario, CA facility.
High risk -
DrugsJabil Inc.
FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.
High risk -
DrugsTianjin Kilo Pharmaceutical Sci-tech Co., Ltd.
Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.
High risk -
DrugsFairyGene, Inc.
FDA cites FairyGene, a Bristol, PA contract manufacturer, for unsanitary facility and cleaning practices and for selling five unapproved drug balms.
High risk -
DrugsLico Industries, LLC., d.b.a. American Towelette Company
FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.
High risk -
DrugsBioMylz Pvt. Ltd.
FDA found destroyed records, inadequate process and cleaning validation, missing microbial testing, and incomplete drug listings at BioMylz, an Indian OTC drug manufacturer.
High risk -
DrugsShimoga Chemicals
FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.
High risk -
FoodMineral BioSciences, LLC
Mineral BioSciences’ Totala and Ionicell supplements were flagged as unapproved new drugs and misbranded, with manufacturing violations.
High risk -
DrugsFareva Amboise
FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.
High risk -
DrugsSpa De Soleil, Inc.
FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.
High risk -
FoodNutratech, LLC
FDA cited Nutratech, LLC for manufacturing violations and an undeclared allergen in dietary supplements.
High risk -
DrugsWizcure Pharmaa Private Limited
FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.
High risk -
DrugsIDO Pharm Co., Ltd.
IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.
High risk -
AnimalRidley USA Inc.
Ridley USA's Iowa City medicated feed plant put monensin into cattle feed instead of the intended drug, killing at least 16 cattle.
High risk -
DrugsAva Inc.
FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.
High risk -
FoodNature’s Elements, Inc.
Nature's Elements sold supplement powders with disease claims as unapproved drugs and made them with no required manufacturing records, FDA says.
High risk -
DrugsLexia LLC
FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.
High risk -
DrugsIntas Pharmaceuticals Limited
FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.
High risk -
DrugsPro Numb Tattoo Numbing Spray, LLC
FDA cited Pro Numb Tattoo Numbing Spray for selling unapproved, misbranded numbing drugs and manufacturing quality failures after a November 2025 inspection.
High risk -
DrugsPurolea Cosmetics Lab
Purolea Cosmetics Lab drug products were adulterated by insanitary conditions and manufacturing failures, and two Dermveda products are unapproved new drugs.
High risk -
AnimalHenan Lvyuan Pharmaceutical Co. Ltd.
FDA warns Henan Lvyuan Pharmaceutical over CGMP failures at its API plant, including water leaks and incomplete batch records.
High risk -
DrugsYangzhou H&R Plastic Daily Chemical Co., Ltd.
Yangzhou H&R Plastic Daily Chemical, a Chinese contract manufacturer, lacked release testing and CGMP controls for its OTC drug.
High risk -
DrugsPatcos Cosmetics Pvt. Ltd.
Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.
High risk -
DrugsAQ USA Inc., d.b.a Ross Healthcare Inc.
FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.
High risk -
DrugsChemspec Chemicals Private Limited
FDA warns Indian API maker Chemspec Chemicals over missing batch records and data integrity failures.
High risk -
DrugsLiquidCapsule Manufacturing, LLC
LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.
High risk